Improving diagnostics and treatment for urological cancers
Development of Diagnostics and Treatment of Urological Cancers
This study is trying out new technologies to see if they can improve how doctors diagnose and treat urological cancers like prostate, kidney, and bladder cancers for better, personalized care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Helsinki University Central Hospital Academic / other |
| Locations | 1 site (Helsinki, Uusimaa) |
| Trial ID | NCT02994758 on ClinicalTrials.gov |
What this trial studies
This study evaluates the use of advanced technologies, such as next generation sequencing and drug sensitivity testing, to enhance the diagnosis and treatment of various urological cancers, including prostate, kidney, and bladder cancers. By collecting high-quality patient samples and linking them to clinical data, the research aims to facilitate the translation of basic research into clinical practice, ultimately leading to personalized medicine approaches. The project seeks to establish a systematic framework for the collection and interpretation of biological samples, ensuring that both clinicians and researchers can access vital information while maintaining patient privacy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a verified diagnosis of urological cancer.
Not a fit: Patients who are unable to provide informed consent or have severe psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved outcomes and personalized treatment options for patients with urological cancers.
How similar studies have performed: Other studies utilizing advanced molecular characterization and personalized medicine approaches have shown promise in improving treatment outcomes for cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The patient is able to provide written informed consent and is at least 18 years of age 2. The patient must have a verified diagnosis of an urologic cancer by a board-certified clinician Exclusion Criteria: 1. The patient is not willing to provide a written informed consent 2. The patient has a severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent
Where this trial is running
Helsinki, Uusimaa
- Helsinki University Hospital — Helsinki, Uusimaa, Finland (Recruiting)
Study contacts
- Principal investigator: Antti S Rannikko, MD, PhD — Helsinki University Central Hospital
- Study coordinator: Antti S Rannikko, MD, PhD
- Email: antti.rannikko@hus.fi
- Phone: +35894711
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.